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Introduction
I. Galactosylceramide Background
In 1993, Koezuka and coworkers were researching marine natural products with anti-tumor
activities at the Kirin Brewery, which led to the discovery of agelasphin (e.g. agelasphin 9b). Research1
on these natural products led to the creation of the KRN7000 (Figure 1).

Figure 1: Structures of Agelasphin 9b and KRN7000

KRN7000 has been reported to stimulate NKT cells through its presentation by the CD1d
protein. This stimulatory pathway may have potential for the treatment of tumors,2-3 infectious diseases,4-5
and autoimmune conditions6-7. Further studies involving alterations to this molecule are being
investigated to observe how differences in glycolipid functionality alter immune responses. In the
following paragraphs the structure and bioactivity of some of the glycolipids related to the goals of this
thesis will be discussed.
A. Composition Of A Galactosylceramide
Generally, a galactosyl ceramide (a type of glycolipid) (Figure 2) is made up of a galactosyl
moiety connected to a ceramide by what is known as a glycosidic bond. The ceramide consists of two
hydrophobic lipid chains, one an amide acyl chain and the other a sphinganine, either of which can vary
based on chain length, branching, or functional groups attached. In the next section the influence of some
glycolipids on the immune system will be presented.

Figure 2: General Structure of Galactosylceramides

B. Immunomodulation
Glycolipids have been shown to increase immunoactivity by interacting with the immune systems
lymphocytes.8 Lymphocytes are white blood cells that serve various functions in the immune system.
They are also related to adaptive immunity (immunity that develops as we age), as opposed to innate
immunity (basic immunity that responds immediately but non-specifically to infections and pathogens).9
The two major classes of lymphocytes are distinguished by cells which grow independently of the thymus
(B cells) and that grow inside the thymus (T cells). Natural Killer T-lymphocytes (NKT cells) are a subset
of lymphocytes that have T-cell receptors located on their surface.9 The glycolipid’s alkyl chains are
utilized by binding to the CD1d protein of an antigen presenting cell through crevice-like tunnels. Once
bound, the exposed sugar head of the glycolipid interacts with the T-cell receptor of the NKT cell.
Interaction between the T-cell receptor and glycolipid causes the release of cytokines from the NKT
cells.10 There are two groups of cytokines, T helper 1 (Th1) and T helper 2 (Th2), categorized based on
their response upon release. Cytokines like interferon-γ (IFN- γ) and interleukin-2 (IL-2) exhibit an
inflammatory response (Th1) associated with controlling bacterial, parasitic and viral infections as well as
tumors. Interleukin-4 (IL-4) and IL-10 are examples of two cytokines responsible for an
immunomodulatory response (Th2), which has been known to ameliorate autoimmune diseases, such as
multiple sclerosis, lupus, rheumatoid arthritis, and type I diabetes.10 In the next section the research
leading to the discovery of KRN7000 and its biological activity will be discussed.

II. Discovery Of KRN7000
In 1993, Koezuka and coworkers were investigating marine natural products for bioactivity and
came across the agelasphins, in particular, agelasphin 9b (extracted from the sponge Agelas Mauritianus)
(Figure 1). The interestingly rare feature about these agelasphins was their α-glycosidic bonds, as opposed
to the β-glycosidic bonds found in more advanced organisms. Around this time it was also discovered that
glycolipids cause lymphocyte cell proliferation. Further studies11 of the bioactivity led to structural
determination that indicated the C4 hydroxyl group as nonessential for bioactivity and the C3 hydroxyl
group as necessary for T-cell stimulation. Alteration of the lipid chains led to the creation of the
galactosylceramide KRN7000.
KRN7000 is now widely known for its interaction with NKT cells leading to the release of both
Th1 and Th2 cytokines. It has been shown10 that Th2 cytokines can antagonize the Th1 response. Ideally,
controlling which cytokines are released would prove beneficial to those suffering from infectious or
autoimmune diseases. Interest surrounding the medicinal properties of the glycolipid led researchers to
investigate methods to manipulate the molecule resulting in the controlled release of Th1 and Th2
cytokines. In the next section previous research involving key KRN7000 derivatives that lead to a biased
cytokine response will be discussed, including background information leading to the target structures of
this thesis.

III. Research On KRN7000 Analogs
A. OCH – A Th2 Biasing Glycolipid
Among the analogs of KRN7000 is OCH (Figure 3), a compound which showed bias in the
release of Th2 cytokines, IL-4 and IL-10. Further studies showed that OCH inhibited experimental
autoimmune encephalitis12 and collagen-induced arthritis13. Inspired by the ameliorative implications,

Miyake and coworkers researched the glycolipid’s (Figure 3) effect on type 1 diabetes. Tests were
conducted on non-obese diabetic mice (NOD), a model for type I diabetes in humans. KRN7000 was used
as a control to test the activity of OCH.

Figure 3: Structure of OCH

While observing the incidence of diabetes in 30 week old NOD mice that were given multiple doses of
OCH at 5 weeks of age, the glycolipid showed comparable inhibition results (reduction from 75% to
27%) to KRN7000. In an experiment observing insulitis (inflammation of islets of the pancreas, which
can lead to diabetes), the inflammations were categorized by the amount of inflamed areas observed
(Figure 4).
To observe levels of insulitis pancreatic sections were removed and examined. Data showed
lower grade 3 levels and higher grade 0 levels in mice dosed with OCH compared to mice dosed with
KRN7000. Although OCH was not as potent in the stimulation of NKT cells (as KRN7000), the
glycolipid showed more inhibitory effect of insulitis in the microscopic appearance of pancreatic samples.
Overall, OCH has provided evidence indicating its inhibition of insulitis and diabetes.14

Figure 4: Levels of insulitis inflammation

OCH test results have been debated14 between researchers trying to determine plausible reasons
for its superiority over KRN7000 in models for diabetes. Variables, such as defects in NKT cells,14 might
have led to an increase of NKT cells in transgenic mice, which would give off more Th2 cytokines,
contaminating the accuracy of the results for cytokine release. The results for the spontaneous
development of diabetes could have been shifted in favor of the OCH glycolipid if there were any
bacterial infections in the mice, because a combination of mycobacterium extract with KRN7000 would
cause the NKT cells to predominately produce Th1 cytokines,15 nullifying the Th2 effect. Although these
are not definitively the reasons behind the results, the fact remains that OCH has shown a biased release
of Th2 cytokines, IL-4 and IL-10, and has assisted validation of the pursuit of altering the glycolipid
structure to provide controlled responses. Another area of interest concerning the alteration of the
glycolipid structure and controlled cytokine release is the glycosidic bond between sugar and ceramide.

Discussion below will focus more on research concerning the glycosidic bond between sugar and
ceramide.

B. Anomeric Replacement: α-C-GalCer
It is known that KRN7000 releases high levels of both Th1 and Th2 cytokines (i.e. IFN-γ and IL4, respectively, are generally monitored). Moreover, the unbiased release antagonizes the health benefits
related to both types of cytokines. Research16 on encephalomyelitis in mice has shown that a synthetic
analogue possessing a truncated sphingosine chain resulted in stimulating of the release of only IL-4,
which better protected mice from encephalomyelitis. This alteration to the glycoside led researchers16-17 to
synthesize a KRN7000 derivative with a hydrophobic methylene (CH2) as the glycosidic link between the
sugar and ceramide instead of the hydrophilic oxygen (O) (Figure 5). The substitution was meant to deter
α-galatosidase catabolism in vivo18-19 and allow observation of any difference in NKT cell stimulation.
HO
HO
HO

OH
O

O

C25H51
NH OH

H2C
C14H29
OH
a-C-GalCer

Figure 5: Franck and Tsuji’s methylene galactosylceramide17

In multiple comparisons between KRN7000 and α-C-GalCer, test results consistently provided
data17,20-21 which led to the conclusion that α-C-GalCer is a better candidate for the treatment of infectious
and autoimmune diseases than KRN7000. Comparison tests17 regarding malaria have shown that α-CGalCer’s antimalaria effect lasted 3 days longer than KRN7000. In regards to tumor studies20 α-C-GalCer
has been shown to exhibit similar T cell stimulation to KRN7000 when using a dosage 1000 times less
than KRN7000. A binding stability experiment20 showed that α-C-GalCer required less time to bind to
NKT cells and stimulated the cells more significantly than KRN7000. In more recent studies,21 α-C-

GalCer was used as an adjuvant to a live attenuated influenza virus vaccine and was shown to increase the
immunogenicity and enhance protection provided by the vaccine in wild type mice. The next section will
discuss previous research conducted in the Howell group focusing particularly on the glycosidic bond.
C. α-S-GalCer
The emerging understanding and medicinal potential of the α-glycosylceramides had
attracted the attention of the Howell group.10 Previous research in our group related to glycolipids was
inspired by the KRN7000 derivative α-C-GalCer. The comparison of the CH2 glycolipid to KRN7000 has
previously been discussed and has led to the conclusion that alterations to the glycosidic bond can have
biased and beneficial effects. Following that approach an investigation22 was conducted exploring the link
between the sugar and ceramide. One previous glycolipid target in the group was α-S-GalCer 3.
This approach took advantage of treating a nucleophilic ceramide with an electrophilic sugar
donor. Ceramide 1 (Scheme 1) was treated with phosphorus pentasulfide forming 2. Glycosylation was
attempted using a trichloroacetimidate activated by a Lewis acid but unfortunately no desired product 3
was isolated. Thiol glycosylation following the above method had been previously reported
successfully23, but researchers used simple alkyl acceptor groups in comparison to the ceramide.

Scheme 1: Glycosylation of a protected α-S-GalCer

Another approach was attempted, targeting α-S-GalCer (Scheme 2). Beginning with phytosphingosine 4,
the molecule was Boc-protected, fully silyl protected, selectively deprotected, and then brominated
following Yamamoto’s procedure forming the electrophilic alkyl chain, 5. Following precedent
literature22 α-S-GalCer 7 was synthesized as an inseparable anomeric mixture. The thiol sugar was then

alkylated using Schimdt’s reported approach, resulting in the protected glycolipid 6. The thiol glycoside
was fully deprotected and acylated to form the targeted α-S-GalCer 7.

Scheme 2: Synthesis of α-S-GalCer

The successfully synthesized α-S-GalCer was tested for biological activity,22 and although it
shared a similar structure to KRN7000, it did not show any biological activity. One speculation was that
oxidation of the thiol glycoside could have occurred, interfering with interaction between the S-GalCer
and NKT cell. Although the S-GalCer may not have shown beneficial effects in regards to NKT cell
stimulation, it provided information regarding substitution of oxygen with a closely related atom.
Continuation of the glycosidic link investigation by the Howell group led to the goals of this thesis.

IV. Target Of Research (α-N-GalCer)
The goals of this thesis were to synthesize α-N-GalCer 8 and α-N-formyl-N-GalCer 9 (Figure 6).
These targets were chosen because we were inspired by α-C-GalCer’s bioactivity and wanted to
synthesize glycosylceramides that carried similarities but had not been explored previously. The next two
sections will discuss literature methods used to approach N-glycosides.

Figure 6: Target α-N-GalCer molecules

A. Approach To α-N-GalCer’s
As with S-GalCer’s there are two main approaches to synthesizing N-glycosides. The first
couples an electrophilic sugar donor with an amine. The next method utilizes a nucleophilic sugar coupled
with an electrophile.
Some researchers have reported creating alkylglycosylamines by coupling simple aminoalkyl
groups with unprotected sugar donors (Scheme 3).24-25 In relation to the sugar, mannose commonly
results in alpha glycosylations, while glucose and galactose yield alpha and beta glycosylated products
(beta predominating).26 There have been no reports of the synthesis of N-glycosylceramides. Marisa
Blauvelt, in the Howell group did try to glycosylate an aminoceramide using an unprotected sugar donor,
but the approach was unsuccessful.

Scheme 3: Formation of an alkylglycosylamine using mannose.

An alternative approach would be to use a halide donor sugar. Our group has experience coupling
galactosyl iodides or bromides with ceramides or related sphingoid bases. Consequently we will examine
the reaction of these glycosyl halides with aminoceramides. Glycosylations reported by Jacquelyn
Gervay-Hague26 treated an alpha sugar donor with a sphinganine (acceptor) resulting in an alpha

glycosylated product. To synthesize the first target (8) a similar approach to Jacquelyn Gervay-Hague’s
will be attempted (Figure 7).

Figure 7: Approach to α-N-GalCer

Regarding the second approach to forming α-N-GalCer’s (mentioned above) there have been
reports25 of successfully synthesizing α-N-GalCer’s using nucleophilic sugar donors (Scheme 4). For
example, the synthesis of spicamycin27 involves a nucleophilic sugar donor reacting with an electrophilic
chloropurine. The sugar 10 underwent azide formation using trimethylsilyl azide. Azide 11 was reduced
using hydrogen with Lindlar’s catalyst, forming 12. The heterocylic alkylation via amide coupling formed
13.

Scheme 4: Formation of alkylglycosylamine using galactose.

B. Approach To α-N-formyl-N-GalCer
A proposed method to the synthesis of α-N-formyl glycolipids was found in recent chemistry28
performed by Danishefsky’s group. Their investigation of complex chemistry was inspired by the
Passerini reaction29 (Figure 8). The reaction (also referred to as an acyl transfer) called for a carboxylic
acid and an isonitrile resulting in an amide product.

Figure 8: Passerini Reaction.

Danishefsky proposed a mechanism between the isonitrile and carboxylic acid (Figure 9), as illustrated in
a reported reaction using a fully protected isonitrile and aspartic acid (Scheme 5). This reactions outcome
has been shown to be influenced anomerically by the isonitrile used for the acyl transfer; an alpha
isonitrile would result in an alpha formylated product and a beta isonitrile would result in a beta
formylated product.

Figure 9: Danishefsky’s proposed acyl transformation.

Scheme 5: Acyl transfer using tetrabenzylated isonitrile and aspartic acid.

Our initial approach to α-N-formyl-N-GalCer 9 will take advantage of Danishefsky’s method
(discussed above) to form N-formyl glycolipids. An alpha nucleophilic sugar donor will be treated with an
electrophilic ceramide acceptor (Figure 10) to synthesize our desired formyl product.

Figure 10: Approach to α-N-formyl-N-GalCer

V. Summary
Past research has shown that KRN7000 anomeric replacements (e.g. α-C-GalCer) have produced
interesting results. Further investigations on these replacements would lead to a better understanding of
the glycolipid structure and potentially biased T cell stimulation. The Howell group’s research has
reported that it is possible to synthesize α-S-galactosylceramides. The investigations in this thesis have
been focused on anomeric replacement with nitrogen.

Results and Discussion
I. Research Objective
The goals of these studies were:
1. To synthesize an α-N-galactosylceramide analog of KRN7000
2. To synthesize an α-N-formyl-N-galactosylceramide analog of KRN7000
3. To compare NKT cell stimulatory abilities of α-N-galactosylceramide and α-N-formylN-galactosylceramide to their parent compound KRN7000 in collaboration with the lab
of Professor Brian Wilson of the University of Florida

II. Synthesis Of α-N-galactosylceramide
A simple and straightforward method was required for the synthesis of the complex structure of
α-N-galactosylceramide. Since the Howell group had success with coupling galactosyl halides with
ceramides or related sphingoid bases this method was examined first. As mentioned before (Figure 7, pg.

10), the glycolipid will be broken down into two groups an aminoceramide and a halosugar. The ceramide
will be synthesized by coupling a fatty acid chain with phytosphingosine.
Following Sanghee’s reported30 α-GalCer approach (Scheme 6), the synthesis of α-N-GalCer
began by coupling commercially available cerotic acid with N-hydroxysuccinimide, providing ester 14a
in 43% yield. Due to the esters less than moderate yields an alternate ester formation was examined.31
Cerotic acid was treated with p-nitrophenol to afford ester 14b in 60% yield. Ester 14b could be isolated
using column chromatography, but it was also found that purification of 14b could be accomplished by
recrystallization using ethyl acetate giving 75% yield. The ester was then coupled to phytosphingosine,
forming ceramide 15, isolated in 99% yield. Previously this had been purified via column
chromatography, but it was discovered that 15 could also be purified by recrystallization using ethyl
acetate. Ceramide 15 was then fully silyl protected, providing 16 in 93% yield. Selective deprotection
gave the free primary alcohol 17 in 62% yield. The original procedure30 called for 10% trifluoroacetic
acid (TFA), but the reaction did not reach completion until the concentration of TFA was increased to
50%. An amination similar to the Gabriel synthesis32 was then performed on alcohol 17. The selectively
deprotected ceramide was treated with phthalimide under Mitsunobu conditions, forming 18 in 76% yield.
Selective deprotection of 18 using hydrazine was attempted. Although the starting material was
consumed, based on TLC, we were unable to isolate clean aminoceramide 19. As proof of aminoceramide
formation, it was acetylated. Although pure acetylated product was not isolated, 13C NMR data from the
acetylation showed two carbonyl peaks, which led us to believe that aminoceramide 19 was successfully
synthesized. The glycosylation of 19 was attempted but no desired product was isolated. Consequently,
the approach was revised.

Scheme 6: Attempted synthesis of aminoceramide

The Howell group has found that working with sphinganines (aminodiols) rather than
phytosphingosines (aminotriols), is sometimes more straightforward. We decided to proceed with the
synthesis using a protected sphinganine (Figure 11). Prior to the ceramide formation the aminodiol will be
coupled with the halosugar donor. The sphingoid base will be formed using a simple and selective route.33
HO

OH
O

HO

HO
O

C25H51
HO

HN

HO
HN

OH
O

C15H31
OH

HO
HN

HO
NHBoc
C15H31
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O
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H2N
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Figure 11: Approach to revised α-N-GalCer

Following a procedure developed in the group33 (Scheme 7) the synthesis of the selectively
protected sphingoid base began by treating Boc-protected serine with methoxy(methyl)amine
hydrochloride, forming Weinreb amide 20. This was treated with two equivalents of a sacrificial base to
deprotonate the primary alcohol of the carbonate. Then, pentadecylmagnesium bromide was added,
forming ketone 21 in 62% yield over two steps. The alcohol was silyl protected, providing 22 in 85%
yield. The protected sphinganine was then reduced, giving the secondary alcohol 23 in 50% yield.
Benzylation gave the fully protected sphingoid base 24 in 54% yield. Selective deprotection provided 25
in 25% yield. The low yield in the deprotection was due to loss of material during work-up. The primary

amine was formed following the same procedure described in the attempted synthesis of the
aminoceramide 19. Reaction with phthalimide gave 26 in 61% yield. A deprotection was attempted using
sodium borohydride with acetic acid in isopropyl alcohol,34 but no desired product was isolated. An
alternate deprotection with hydrazine produced 27 in 25% yield. During purification of the phthalimide
deprotection via TLC plate a second spot was observed close to the desired product. This had also been
observed with the attempted aminoceramide purification. The 1H and 13C NMRs showed only the desired
aminodiol in the isolated product.

Scheme 7: Synthesis of sphingoid base

The synthesis of the glycosyl donor began with commercially available methyl-α-Dgalactopyranoside(28) (Scheme 8). Following the approach of Jacquelyn Gervay-Hague’s reported
halosugar synthesis,35 global benzyl protection of methoxygalactoside, followed by anomeric hydrolysis
gave 29 in 9% yield over two steps. Acetalyation of the lactol formed 30. Purification of 30 did not afford
a sufficient yield so the product was obtained by a labmate. Treatment of the acetylated sugar with
hydrobromic acid provided bromosugar 31. Due to its sensitivity to silica gel, the sugar was directly used
in the glycosylation without purification.

Scheme 8: Synthesis of bromosugar

Glycosylation of the protected aminosphingoid base 27 with bromosugar 31 was performed
following a method reported by Jacquelyn Gervay-Hague (Scheme 9).26 A compound that displayed
similar spectral characteristics to the desired product was observed but, unfortunately, could not be
isolated.

Scheme 9: Attempted synthesis of revised α-N-GalCer

III. Synthesis Of α-N-formyl-N-galactosylceramide
Our synthesis of α-N-formyl-N-galactosylceramide (9) will require treatment of an electrophilic
sugar with a nucleophilic ceramide (Figure 12). Based on the study reported by Danishefsky28 (Scheme 5,
pg. 12) we will treat an isonitrile with a carboxylic acid derived from the corresponding ceramide. The
beta isonitrile will be used to test the methodology of the acyl transfer reaction. Once the methodology
proves successful, the alpha isonitrile will be used to create the desired N-formyl glycolipid. The isonitrile
will be synthesized using Danishefsky’s methods, and the acid will be synthesized by oxidation of the
ceramide’s primary alcohol.
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Figure 12: Approach to α-N-formyl-N-GalCer

A model study was conducted prior to the α-N-formyl-N-GalCer synthesis, to test Danishefsky’s
reported acyl transfer (Scheme 5, pg. 12).28 Commercially available aspartic acid 34 was treated with
isonitrile 33, prepared by labmate Dr. Stewart Richardson, giving 35 in 52% yield (Scheme 10). The
results of this study gave us enough cause to pursue the acyl transfer with ceramide.

Scheme 10: Danishefsky’s reported acyl transfer reaction

The approach towards 9 began with previously synthesized ceramide alcohol 17 (Scheme 6, pg.
14). Following a procedure presented by Danishefsky,28 compound 17 was oxidized to carboxylic acid 36
in 37% yield (Scheme 11). Excess TEMPO and BAIB were necessary to complete the conversion to
carboxylic acid. The acid was then treated with the protected isonitrile 33 to form product 37.
Unfortunately, the desired product from the acyl transfer reaction was not observed.

Scheme 11: Attempted synthesis of α-N-formyl-N-GalCer

Messy TLC and NMR data led to concerns about the stability of the ceramide under the high
temperature reaction conditions. Byproducts observed via TLC showed potential signs of ceramide
decomposition (e. g. deprotections). An alternate approach will be taken to address steric complications
with the ceramide and take advantage of our previously synthesized sphingoid base 25.
The reaction conditions for the acyl transfer reaction reported by Danishefsky appeared to be too
harsh for the ceramide-derived carboxylic acid. It was decided that a simpler structure and different
protecting groups may tolerate the reaction conditions better. The alternative route will use the protected
isonitrile 33 and an oxidized form of the sphingoid base (creating the acid) for the acyl transfer (Figure
13). As stated previously, a beta isonitrile will be used to test the methodology of the acyl transfer with
the sphingoid base.

Figure 13: Revised approach to α-N-formyl-N-GalCer

Sphingoid base 25 (Scheme 7, pg. 16) was oxidized to carboxylic acid 37 in 81% yield (Scheme 12). Acid
38 was reacted with 32 to form the revised α-N-formyl-N-GalCer product 39. Unfortunately no desired
product was isolated, and NMR data showed evidence of byproducts. It was concluded that high
temperatures caused the decomposition of the protected sphingoid base and ceramide which led to the
unsuccessful acyl transfer with the protected isonitrile.

Scheme 12: Attempted synthesis of revised α-N-formyl-N-GalCer

Conclusion
The syntheses of complex amino glycosides have been shown to hold a few obstacles. The
synthesis of the aminoceramide was not completed due to complications during purification. The
acetylation of an isolated aminotriol did suggest that the aminoceramide was synthesized, but in the next
reaction no glycosylated product was isolated. The alternative α-N-GalCer glycosylation using a
sphingoid base, resulted in a compound with similar spectral characteristics to the desired product, but the
glycosylated sphinganine was not isolated. The α-N-formyl-N-GalCer synthesis was also not successful.
Based on 1H NMR and TLC, it appeared that decomposition of the ceramide and sphinganine carboxylic
acids occurred under the reaction conditions.
Future attempts to synthesize amino galactosylceramides will continue to focus on using
aminosphingoid base derivative 35. The α-N-formyl-N-GalCer approach will focus on identifying less
extreme conditions. One approach would use a fully deprotected isonitrile 40 (Figure 14). The formation

of the N-formyl group is driven by hydrogen bonding of the free C2’’ hydroxyl group on the sugar
providing compound 41,36 followed by deprotection of the silyl groups to obtain target 9.

Figure 14: Formation of N-formyl-N-GalCer using unprotected isonitrile

Another approach uses an acylated thiolphenol as opposed to a carboxylic acid in the acyl
transfer reaction.36 The product will be a di-thiophenol substituted carbon 43 (Scheme 13), but this can be
hydrolyzed to the formyl group using p-toluenesulfonic acid in water to afford the α-N-formyl-Ngalactosylceramide product 44, followed by full deprotection to provide desired target 9.

Scheme 13: Formation of N-formyl-N-GalCer using thiophenol

Experimental

General. Melting points were determined in open Pyrex capillary tubes and are uncorrected. Infrared
spectra were recorded on a Nicolet 750 FT-IR spectrometer. 1H NMR spectra were recorded at 300 MHz
on a Bruker Avance Ultrashield 300-NMR spectrometer, at 400 MHz on a Bruker Avance DRX-400
NMR spectrometer, and at 500 MHz on a Bruker Avance 500-NMR spectrometer. Chemical shifts (δ) are
reported in ppm and coupling constants (J) are reported in Hertz. Abbreviations used are as follows: s =
singlet, d = doublet, t = triplet, q = quartet, m = multiplet, br = broad, dd = doublet of doublets, ddd =
doublet of double of doublts, dt = doublet of triplets. 13C NMR spectra were recorded on a Bruker Avance
Ultrashield 300-NMR spectrometer at 75 MHz, on a Bruker Avance DRX-400 NMR spectrometer at 100
MHz, or on a Bruker Avance 500-NMR spectrometer at 125 MHz. High-resolution mass spectra were
determined by the Mass Spectroscopy Facility in the Department of Chemistry at the University of
Connecticut in Storrs, Connecticut and the Mass Spectroscopy Facility in the Department of Chemistry
and Biochemistry at the University of Notre Dame in Notre Dame, Indiana. Column chromatography was
performed with flash silica, 40 microns. Thin-layer chromatography was carried out on silica gel (Silica
Gel 60 F254) glass plates. Spots were visualized by UV and/or 10% molybdic acid in ethanol.
Tetrahydrofuran was obtained from a distillation dispensing unit under neutral alumina (CH2Cl2, pyridine,
and toluene were obtained in the Chemistry Department stock room located at University of Connecticut
in Storrs, Connecticut and dried over 4Ǻ MS).

Hexacosanoic acid 2,5-Dioxo-pyrrolidin-1-yl ester (14a)
Hexacosanoic acid (0.50 g, 1.3 mmol) was dissolved in CH2Cl2 (15 mL) under N2 at rt. EDC (0.27 g, 1.4
mmol) and N-hydroxysuccinimide (0.18 g, 1.6 mmol) were added to the solution. The reaction mixture

was heated to 40 °C for 6 h. The reaction was diluted with H2O (10 mL), and the organic layer was
extracted with Et2O (30 mL). The organic layer was then washed with brine (10 mL), dried (MgSO4), and
concentrated under reduced pressure. Purification by flash chromatography on silica gel (PetEt/EtOAc
85:15) afforded 14a as a white solid (0.28 g, 43%):33 1H NMR (300 MHz, CDCl3) δ 2.83 (s, 4H), 2.59 (t,
J = 7.5 Hz, 2H), 1.74 (m, 2H), 1.39 (m, 2H), 1.25 (m, 42H), 0.87 (t, J = 6.8 Hz, 3H); 13C NMR (75 MHz,
CDCl3) δ 169.1, 168.6, 31.9, 30.9, 29.7, 29.6, 29.5, 29.3, 29.1, 28.8, 25.6, 24.5, 22.7, 14.1
O
O2N

O

C25H51

p-Nitrophenyl hexacosanoate (14b)
Hexacosanoic acid (1.0 g, 2.5 mmol) was dissolved in CH2Cl2 (260 mL) under N2 at rt. p-Nitrophenol
(0.39 g, 2.8 mmol), DMAP (0.060 g, 0.51 mmol), and DCC (0.55 g, 2.7 mmol) were added to the reaction
flask, and the mixture was stirred for 8 h. The solution was filtered, and the filtrate was concentrated
under reduced pressure. Purification by recrystallization (EtOAc) afforded 14b as a yellow solid (0.98 g,
75%):31 1H NMR (400 MHz, CDCl3) δ 8.29 (d, J = 9.1 Hz, 2H), 7.30 (d, J = 9.3 Hz, 2H), 2.62 (t, J = 7.5
Hz, 2H), 1.78 (m, 2H), 1.28 (m, 44H), 0.90 (t, J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 171.3,
155.5, 145.2, 125.2, 122.4, 34.3, 31.9, 29.7, 29.7, 29.6, 29.6, 29.4, 29.4, 29.4, 29.2, 29.0, 24.7, 22.7, 14.1.

Hexacosanoic acid (2,3-Dihyroxy-1-hydroxymethylheptadecyl) amide (15)
p-Nitrophenyl hexacosanoate (14b) (0.46 g, 0.89 mmol) was dissolved in pyridine (17 mL) under N2 at rt.
Phytosphingosine (0.23 g, 0.74 mmol) was then added, and the solution was allowed to stir for 65 h. The
solution was then concentrated under reduced pressure. Purification by recrystallization (EtOAc) afforded
15 as a yellow solid (0.51 g, 99%):30 1H NMR (500 MHz, pyr) δ 8.34 (d, J = 8.5 Hz, 1H), 5.10-5.05 (m,

1H), 4.49 (m, 1H), 4.45 (m, 1H), 4.33 (m, 1H), 4.23 (m, 1H), 2.46 (t, J = 7.3 Hz, 2H), 2.18-1.21 (m,
72H), 0.88 (t, J = 6.7 Hz, 6H).

(2S,3S,4R)-1,3,4-Tri-t-butyldimethylsilyloxy-2-hexacosanoylaminooctadecane (16)
Hexacosanoic acid (2,3-dihyroxy-1-hydroxymethylheptadecyl) amide (15) (1.5 g, 2.2 mmol) was
dissolved in CH2Cl2 (50 mL) at 0 °C. TBSOTf (4.4 g, 17 mmol) and 2,6-lutidine (3.5 g, 33 mmol) were
added, and the solution was stirred at rt for 10 h. The reaction was quenched with MeOH (12 mL). The
mixture was then diluted with Et2O (100 mL) and washed with H2O (55 mL), saturated aqueous NaHCO3
(55 mL), and brine (55 mL). The organic layer was dried (MgSO4), filtered, and concentrated under
reduced pressure. Purification by flash chromatography on silica gel (petroleum ether/EtOAc 98:2)
afforded 16 as a colorless oil (2.13 g, 93%):30 1H NMR (300 MHz, CDCl3) δ 5.82 (d, J = 8.7 Hz, 1H) 3.94
(m, 1H), 3.87 (dd, J = 9.9, 4.2 Hz, 1H), 3.82 (dd, J = 7.2, 1.2 Hz, 1H), 3.67 (m, 1H), 3.63 (dd, J = 9.9, 4.5
Hz, 1H), 2.14 (t, J = 7.7 Hz, 2H), 1.64-1.46 (m, 6H), 1.25 (m, 66H), 0.93-0.86 (m, 33H), 0.13-0.04 (m,
18H); 13C NMR (75 MHz, CDCl3) δ 172.2, 75.4, 75.4, 61.4, 52.5, 37.2, 32.2, 31.9, 30.0, 29.7, 29.5, 29.4,
29.4, 29.4, 26.4, 26.1, 26.1, 25.9, 25.8, 22.7, 18.4, 18.2, 18.2, 14.1, -3.5, -3.8, -4.6, -5.2, -5.2, -5.6.

(2S,3S,4R)-3,4-Bis-tert-butyldimethylsilyloxy-2-hexacosanoylamino-1-octadecanol (17)
(2S,3S,4R)-1,3,4-Tri-t-butyldimethylsilyloxy-2-hexacosanoylaminooctadecane (16) (2.1 g, 2.1 mmol) was
dissolved in dry THF (31 mL) and cooled to -10 °C. TFA (50% in H2O, 0.84 mL, 11 mmol) was slowly
added. The reaction was gradually warmed to 10 °C over 5 h. The solution was quenched with saturated

aqueous NaOH (22 mL) and diluted with Et2O (64 mL). The two layers were separated, and the organic
layer was washed with H2O (31 mL), saturated aqueous NaHCO3 (31 mL), and brine (31 mL), dried
(MgSO4), and concentrated under reduced pressure. Purification by flash chromatography on silica gel
(petroleum ether/EtOAc 80:20) afforded 17 as a colorless oil (1.18 g, 62%):30 1H NMR (300 MHz,
CDCl3) δ 6.24 (d, J = 7.8 Hz, 1H), 4.21 (m, 1H), 4.06 (m, 1H) 3.90 (m, 1H), 3.76 (m, 1H), 3.59 (m, 1H),
3.15 (m, 1H) 2.18 (t, J = 7.5 Hz, 2H), 1.48-1.62 (m, 6H), 1.25 (m, 66H), 0.93 (s, 9H), 0.91 (s, 9H), 0.850.94 (m, 6H), 0.11 (s, 6H), 0.08 (s, 6H); 13C NMR (75 MHz, CDCl3) δ 172.6, 77.5, 76.4, 63.6, 51.3, 37.0,
34.4, 31.9, 29.8, 29.7, 29.6, 29.5, 29.5, 29.4, 26.0, 26.0, 25.8, 25.6, 22.7, 18.2, 16.9, 14.1, -3.8, -4.1, -4.5,
-4.9.

(2S,3S,4R)-2-(N-Pentacosanoylamino)-3,4-di-t-butyldimethylsilanyloxy-1-octadecaphthalimide (18)
(2S,3S,4R)-3,4-Bis-tert-butyldimethylsilyloxy-2-hexacosanoylamino-1-octadecanol (17) (0.16 g, 0.18
mmol) was dissolved in dry THF (26 mL) under N2 at rt. Triphenylphosphine (0.23 g, 0.88 mmol), DIAD
(0.039 g, 0.19 mmol), and phthalimide (0.031 g, 0.21 mmol) were added, and the solution was stirred for
3.5 h. The mixture was concentrated under reduced pressure. Purification by flash chromatography on
silica gel (petroleum ether/EtOAc 95:5) afforded 18 as a clear oil (0.14 g, 76%): [α]25D -5.19 (c 1.4,
CHCl3); IR (KBr) 2924, 2854, 1717, 1683 cm-1; 1H NMR (400 MHz, CDCl3) δ 7.83 (dd, J = 2.4, 5.4 Hz,
2H), 7.72 (dd, J = 2.4, 5.4 Hz, 2H) , 5.98 (d, J = 8.1 Hz, 1H), 4.42 (m, 2H), 3.81 (m, 3H), 2.12 (ddd, J =
7.6, 7.6, 7.6 Hz, 1H), 2.01 (ddd, J = 7.6, 7.6, 7.6 Hz, 1H), 1.70 (m, 4H), 1.60 (m, 4H), 1.41 (m, 4H), 1.28
(br, s, 60H), 1.02 (s, 9H), 0.95 (s, 9H), 0.90 (m, 6H), 0.13 (m, 12H) 13C NMR (100 MHz, CDCl3) δ 172.8,
169.1, 134.2, 132.2, 123.4, 51.1, 37.8, 37.1, 34.6, 32.1, 30.0, 29.9, 29.9, 29.8, 29.8, 29.6, 29.5, 29.4, 26.3,

26.3, 26.1, 25.6, 22.9, 18.6, 18.4, 14.3, -3.3, -3.8, -4.3, -4.7; HRMS (TOF) calcd for C64H121N2O5Si2 (M+
+ H) 1053.8814. Found 1053.8859.

[2-Hydroxy-1-(methoxymethylcarbamoyl)ethyl]carbamic acid tert-butyl ester (20)
Boc-L-serine (6.00 g, 29 mmol) was dissolved in dry CH2Cl2 (115 mL) and the solution cooled to -15 °C
under N2. N,O-Dimethylhyroxylamine hydrochloride (3.0 g, 30 mmol) was added, followed by Nmethylmorpholine (3.1 g, 30 mmol). After 5 min 1-(3-methylaminopropyl-3-ethylcarbodoiimide
hydrochloride (5.8 g, 30 mmol) was added in five portions over 30 min. After being stirred for 1 h at -15
°C, the reaction was quenched with HCl (1 M, 17 mL), and the layers were separated. The aqueous layer
was extracted with CH2Cl2 (3 x 34 mL). The organic extracts were combined, washed with saturated
NaHCO3 (17 mL) and H2O (17 mL), dried (MgSO4), and concentrated to provide 20 as a white solid (5.55
g, carried to the next step without purification):33 1H NMR (400MHz, CDCl3) δ 5.71 (br, s, 1H), 4.95 (br,
s, 1H), 3.82-3.78 (m, 5H), 3.23 (s, 3H), 2.90 (br s, 1H), 1.43 (s, 9H).

(2S)-2-(N-tert-Butoxycarbonyl)amino-1-hydroxyoctadecan-3-one (21)
[2-Hydroxy-1-(methoxymethylcarbamoyl)ethyl]carbamic acid tert-butyl ester (20) (15 g, 59 mmol) was
dissolved in dry THF (117 mL) under N2. The solution was cooled to -15 °C, and isopropylmagnesium
chloride (60 mL, 2 M) was added dropwise, affording a clear solution. After 5 min, pentadecylmagnesium
bromide (0.26 M in THF, 212 mL, 76 mmol) was added at -15 °C. The resulting solution was allowed to
warm to rt overnight. The mixture was cooled to -15 °C, and HCl (1 M, 180 mL) was added, followed by
EtOAc (135 mL). The two layers were separated, and the aqueous layer was extracted with CH2Cl2 (3 x

30 mL). The organic extracts were combined, washed with H2O (270 mL), dried (MgSO4), and
concentrated. Purification by flash chromatography on silica gel (petroleum ether/EtOAc 85:15) afforded
21 as a white solid (14 g, 62% over two steps):33 1H NMR (400 MHz, CDCl3) δ 5.48 (br s, 1H), 4.26 (m,
1H), 3.94 (m, 2H), 2.63 (br s, 1H), 2.55 (m, 2H), 1.57 (m, 2H), 1.45 (s, 9H), 1.27-1.22 (m, 24H), 0.88 (t, J
= 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 208.1, 164.0, 80.3, 70.1, 68.9, 63.3, 61.6, 52.3, 49.8, 39.9,
31.9, 29.7, 29.6, 29.4, 29.3, 29.2, 28.3, 23.5, 22.7, 14.1.

(2S)-2-(N-tert-Butoxycarbonyl)amino-1-tert-butyldiphenylsilanyloxyoctadecan-3-one (22)
A catalytic amount of DMAP was added to a stirred solution under N2 of (2S)-2-(N-tertbutoxycarbonyl)amino-1-hydroxyoctadecan-3-one (21) (7.4 g, 19 mmol) and imidazole (3.8 g, 56 mmol)
in dry DMF (21 mL). After 20 min TBDPSCl (6.1 g, 22 mmol) was added dropwise, and the reaction
mixture was stirred overnight. In the morning the reaction was diluted with saturated aqueous NH4Cl (50
mL), and the aqueous layer was extracted with CH2Cl2 (37 mL). The organic layer was washed with H2O
(37 mL) and brine (37 mL), dried (MgSO4), and concentrated. Purification by flash chromatography on
silica gel (petroleum ether/EtOAc 98:2) afforded 22 as a clear oil (10 g, 85%):33 1H NMR (400 MHz,
CDCl3) δ 7.60 (m, 4H), 7.39 (m, 6H), 5.53 (d, J = 7.7 Hz, 1H), 4.33 (m, 1H), 4.04 (dd, J = 10.6, 3.1 Hz,
1H), 3.90 (dd, J = 10.9, 3.8 Hz, 1H), 2.51 (m, 2H), 1.58 (m, 2H), 1.44 (s, 9H), 1.26 (m, 24H), 1.03 (s,
9H), 0.89 (t, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 207.4, 155.3, 135.5, 132.8, 129.9, 129.9,
127.8, 79.8, 64.2, 61.3, 60.3, 41.3, 40.0, 32.1, 29.7, 29.6, 29.6, 29.4, 29.4, 29.3, 29.2, 29.0, 28.3, 27.6,
26.7, 26.2, 23.3, 22.7, 22.6, 20.9, 20.4, 19.4, 19.2, 18.7, 14.3.

(2S,3R)-2-(N-tert-Butoxycarbonyl)amino-1-tert-butyldiphenylsilanyloxyoctadecan-3-ol (23)

LiAl(O-t-Bu)3H (1.1 g, 4.3 mmol) was added to dry EtOH (7.6 mL) at -78 °C under N2. (2S,3R)-2-(Ntert-Butoxycarbonyl)amino-1-tert-butyldiphenylsilanyloxyoctadecan-3-one (22) (0.46 g, 0.72 mmol) in
dry EtOH (7.6 mL) was added to the reaction flask dropwise. After stirring for 6 h at -78 °C the reaction
mixture was diluted with CH2Cl2 (2.2 mL) and neutralized with 10% citric acid (22 mL). The solution
was allowed to stir and reach rt over 1.5 h. The cloudy suspension was extracted with CH2Cl2 (3 x 7 mL).
The organic extracts were combined and washed with H2O (4 x 7 mL). The organic layer was then
washed with brine (7 mL), dried (MgSO4), and concentrated. Purification by flash chromatography on
silica gel (petroleum ether/EtOAc 95:5) afforded 23 as a clear oil (0.23 g, 50%):33 1H NMR (300 MHz,
CDCl3) δ 7.62 (m, 4H), 7.41 (m, 6H), 5.30 (d, J = 8.1 Hz, 1H), 3.93 (m, 1H), 3.90 (m, 1H), 3.67 (m, 1H),
3.57 (br s, 1H), 2.88 (m, 2H), 1.44-1.06 (m, 45H), 0.87 (t, J = 7.0 Hz, 3H); 13C NMR (75 MHz, CDCl3) δ
155.9, 135.8, 132.8, 132.7, 130.2, 130.1, 128.1, 128.0, 79.6, 74.0, 64.4, 54.7, 34.7, 32.1, 31.1, 29.8, 29.6,
28.6, 27.1, 26.1, 22.9, 19.4, 14.3.

(2S,3R)-2-(N-tert-Butoxycarbonyl)amino-1-tert-butyldiphenylsilanyloxy-3-benzyloxyoctadecane (24)
(2S,3R)-2-(N-tert-Butoxycarbonyl)amino-1-tert-butyldiphenylsilanyloxyoctadecan-3-ol (23) (0.14 g, 0.21
mmol) was dissolved in dry DMF (1 mL) under N2 and cooled to 0 °C. Tetrabutylammonium iodide (0.12
g, 0.32 mmol) and sodium hydride (60% in mineral oil, 0.0070 g, 0.30 mmol) were then added. After 15
min benzylbromide (0.055 g, 0.32 mmol) was added dropwise via syringe. The solution was allowed to
stir at 0 °C for an additional 15 min before it was removed from the cooling bath and allowed to stir at rt
for 45 min. The reaction was then quenched with saturated aqueous NH4Cl (2 mL), and the solution was
extracted with EtOAc (4 x 3 mL). The combined organic extracts were washed with H2O (3 mL) and
brine (3 mL), dried (MgSO4), and concentrated. Purification by flash chromatography on silica gel
(petroleum ether/EtOAc 97:3) afforded 24 as a clear oil (0.085 g, 54%):33 1H NMR (300 MHz, CDCl3) δ

7.65 (m, 4H), 7.63-7.27 (m, 11H), 4.71 (d, J = 8.0 Hz, 1H), 4.54 (d, J = 11.3 Hz, 1H), 4.49 (d, J = 11.3
Hz, 1H), 3.86 (m, 2H), 3.72 (dd, J = 9.0, 4.1 Hz, 1H), 3.58 (m, 1H), 1.42 (s, 9H), 1.42 (s, 2H), 1.26 (br s,
26H), 1.05 (s, 9H), 0.88 (t, J = 7.0 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 155.8, 138.8, 135.9, 133.5,
130.0, 128.5, 128.0, 127.7, 79.3, 79.1, 72.3, 63.1, 53.7, 32.2, 30.7, 30.1, 29.9, 29.9, 29.8, 29.6, 28.6, 27.1,
25.6, 22.9, 19.5, 14.4.

(2S,3R)-2-(N-tert-Butoxycarbonyl)amino-3-benzyloxyoctadecan-1-ol (25)
(2S,3R)-2-(N-tert-Butoxycarbonyl)amino-1-tert-butyldiphenylsilanyloxy-3-benzyloxyoctadecane

(24)

(0.15 g, 0.20 mmol) was dissolved in THF (0.8 mL) under N2, and the solution was cooled to 0 °C.
TBAF (0.11 mL, 1.0 M in THF) was added, and the solution was stirred for 4 h at rt. The reaction mixture
was concentrated, and the residue was dissolved in CH2Cl2 (2.4 mL). The solution was washed with brine
(5 mL), dried (MgSO4) and concentrated again. Purification by flash chromatography on silica gel
(petroleum ether/EtOAc 80:20) afforded 25 as a white solid (0.025 g, 25%):33 1H NMR (400 MHz,
CDCl3) δ 7.32 (m, 5H), 5.27 (d, J = 7.4 Hz, 1H), 4.63 (d, J = 11.4 Hz, 1H), 4.48 (d, J = 11.4 Hz, 1H), 3.95
(m, 1H), 3.65 (m, 3H), 2.95 (s, 1H), 1.67 (m, 1H), 1.44 (s, 9H), 1.26 (br s, 27H), 0.88 (t, J = 6.8 Hz, 3H);
13

C NMR (100 MHz, CDCl3) δ 156.2, 138.2, 128.7, 128.1, 128.0, 82.0, 79.6, 73.0, 62.5, 53.5, 32.1, 31.5,

30.0, 29.9, 29.9, 29.8, 29.7, 29.6, 28.6, 25.8, 22.9, 14.3.

(2S,3R)-3-Benzyloxy-2-(N-t-butoxycarbonyl)amino-1-octadecapthalimide (26)
(2S,3R)-2-(N-tert-Butoxycarbonyl)amino-3-benzyloxyoctadecan-1-ol (25) (1.0 g, 2.0 mmol) was
dissolved in dry THF (160 mL) at rt under N2. Triphenylphosphine (2.7 g, 10 mmol), DIAD (0.45 g, 2.2

mmol), and phthalimide (0.36 g, 2.4 mmol) were added, and the solution was stirred for 3.5 h. The
mixture was concentrated under reduced pressure. Purification by flash chromatography on silica gel
(petroleum ether/EtOAc 90:10) afforded 26 as a white solid (0.77 g, 61%): mp 84-88 °C; [α]25D -27.3 (c
3.4, CHCl3); IR (KBr) 2924, 2854, 1717 cm-1: 1H NMR (300 MHz, CDCl3) δ 7.75 (br s, 2H), 7.61 (br s,
2H), 7.24 (m, 5H), 4.87 (d, J = 9.3 Hz, 1H), 4.61 (d, J = 11.7 Hz, 1H), 4.41 (d, J = 11.7 Hz, 1H), 4.06 (br
s, 1H), 3.75 (m, 2H), 3.51 (br s, 1H), 1.69 (br s, 1H), 1.40 (br s, 3H), 1.20 (s, 23H), 1.11 (s, 9H), 0.81 (t, J
= 6.3 Hz, 3H) 13C NMR (75 MHz, CDCl3) δ 168.7, 155.9, 138.6, 133.9, 132.4, 128.6, 127.2, 123.3, 80.7,
79.3, 77.6, 77.2, 76.8, 72.3, 51.8, 38.0, 32.1, 31.2, 30.0, 29.9, 29.9, 29.8, 29.7, 29.5, 28.2, 25.7, 23.1, 22.9,
14.3; HRMS (TOF) calcd for C38H57N2O5 (M+ + H) 621.4267. Found 621.4289.

(2S,3R)-3-Benzyloxy-2-(N-t-butoxycarbonyl)amino-1-octadecamine (27)
(2S,3R)-3-Benzyloxy-2-(N-t-butoxycarbonyl)amino-1-octadecapthalimide (26) (1.5 g, 2.5 mmol) was
dissolved in MeOH (15 mL) at rt under N2. The solution was treated with hydrazine monohydrate (0.18 g,
3.7 mmol) and allowed to stir for 3 h at 65 °C. After 2 h a TLC (CH2Cl2/MeOH 98:2) showed starting
material; so hydrazine (0.060 mL, 1.2 mmol) was added. A white precipitate resulted. After 1 h the
mixture was passed through Celite and concentrated. Purification by flash chromatography on silica gel
(CH2Cl2/MeOH 98:2) afforded 27 as a yellow oil (0.29 g, 25%): [α]25D -11.0 (c 1.7, CHCl3); IR (KBr)
3447, 2924, 2854, 1717 cm-1; 1H NMR (300 MHz, CDCl3) δ 7.21 (m, 5H), 5.01 (d, J = 7.8 Hz, 1H), 4.57
(d, J = 11.4 Hz, 1H), 4.43 (d, J = 11.4 Hz, 1H), 3.59 (m, 1H), 3.48 (m, 1H), 2.80 (br, s, 2H), 1.55 (m, 2H),
1.38 (s, 9H), 1.20 (s, 26H), 0.83 (t, J = 6.3 Hz, 3H) 13C NMR (75 MHz, CDCl3) δ 156.2, 138.8, 128.7,
128.0, 127.9, 81.0, 79.4, 72.5, 54.5, 41.7, 32.1, 31.1, 30.1, 29.9, 29.9, 29.8, 29.7, 29.6, 28.6, 25.8, 22.9,
14.3; HRMS (TOF) calcd for C30H55N2O3 (M+ + H) 491.4213. Found 491.4196.

Methyl 2,3,4,6-tetra-O-benzyl-α-D-galactopyranoside (28)
Sodium hydride (60% in mineral oil, 2.5 g, 103 mmol) in DMF (50 mL) was added to methyl-α-Dgalactopyranoside (28) (2.0 g, 10 mmol) in two fractions. The flask was then placed in a cold water bath
for 30 min. BnBr (11 g, 62 mmol) in DMF (10 mL) was then added to the reaction flask. The reaction
was stirred at rt for 12 h under N2 flow. The solution was neutralized with brine (25 mL), and the organic
layer was extracted with Et2O (50 mL x 3). The combined organic layers were washed with water (50 mL
x 3) and brine (50 mL), dried (MgSO4), and concentrated under reduced pressure. The product was
carried to the next step without further purification.35

2,3,4,6-Tetra-O-benzyl-D-galactopyranose (29)
Methanesulfonic acid (2.1 g, 21 mmol) was dissolved in H2O (10 mL). Methyl 2,3,4,6-tetra-O-benzyl-αD-galactopyranoside (28) (7.9 g, 14 mmol) was dissolved in acetic acid (60 mL). The methanic sulfonic
acid solution was then added dropwise to the galactopyranoside solution. The resultant solution was
heated to 80 °C for 6.5 h. The mixture was then cooled to rt and concentrated under reduced pressure.
Purification by flash chromatography on silica gel (petroleum ether/EtOAc 7:3) afforded 29 as a colorless
oil (0.72 g, 9% over two steps):35 1H NMR (200 MHz, CDCl3) δ 7.40-7.18 (m, 20H), 5.97-4.36 (m, 8H),
5.27 (d, J = 3.6 Hz, 1H), 4.19-3.45 (m, 6H).

1-O-Acetyl, 2,3,4,6-tetra-O-benzyl-β-D-galactopyranose (30)
2,3,4,6-Tetra-O-benzyl-D-galactopyranose (29) (0.72 g, 1.3 mmol) was dissolved in pyridine (3 mL) and
was cooled to 0 °C. Acetic anhydride (0.27 g, 2.6 mmol) was then added to the reaction flask dropwise.
The reaction was stirred overnight. The mixture was diluted with EtOAc (3 mL) and washed with ice cold
water (3 mL). The organic layer was then separated and washed with water (3 mL) and brine (3 mL),
dried (MgSO4), and concentrated under reduced pressure. 1-O-Acetyl, 2,3,4,6-tetra-O-benzyl-β-Dgalactopyranose (30) was not purified.35

2,3,4,6-Tetra-O-benzyl-α-D-galactopyranosyl bromide (31)
1-O-Acetyl, 2,3,4,6-tetra-O-benzyl-β-D-galactopyranose (30) (0.20 g, 0.34 mmol) was dissolved in
CH2Cl2 (9 mL) and cooled to 0 °C. HBr (33% in AcOH) (0.17 mL) was then added to the reaction flask
dropwise. The solution was allowed to stir for 1.5 h. The reaction mixture was then poured over ice cold
saturated aqueous NaHCO3 (10 mL) and stirred slowly. The organic and aqueous layers were separated.
The aqueous layer was extracted with cold EtOAc (10 mL x 3). The combined organic layers were
washed with water (10 mL) and brine (10 mL), dried (MgSO4), and concentrated under reduced pressure.
The product (31) was used without further purification.37

Nα-(Fluoren-9-ylmethyloxycarbonyl)-Nγ-(2,3,4,6-tetra-O-benzyl-β-D-galactopyranosyl)-Nγ-formylL-asparagine-t-butyl-ester (35)
Aspartic acid (34) (0.027 g, 0.066 mmol) was added to 2,3,4,6-Tetra-O-benzyl-β -D-galactopyranosyl
isonitrile (33) (0.025 g, 0.046 mmol) in anhydrous CHCl3 under N2. The reaction mixture was sealed and
heated to 150 °C in a microwave for 45 minutes. Once the reaction was complete the solvent was remove
via reduced pressure. Purification by flash chromatography on silica gel (petroleum ether/EtOAc 3:1)
afforded 35 as a yellow oil (0.023 g, 52%):28 1H NMR (400 MHz, CDCl3) δ 9.3-8.5 (br, 1H), 7.68 (d, J =
7.5 Hz, 2H), 7.53-7.51 (m, 2H), 7.31 (t, J = 7.6 Hz, 2H), 7.26-7.11 (m, 22H), 5.61 (d, J = 9.0 Hz, 1H),
5.48 (d, J = 9.6 Hz, 1H), 4.90 (d, J = 10.8 Hz, 1H), 4.74 (d, J = 10.3 Hz, 1H), 4.65 (d, J = 11.7 Hz, 2H),
4.54-4.48 (m, 2H), 4.43-4.30 (m, 5H), 4.23 (t, J = 7.4 Hz, 1H), 4.15 (m, 1H), 3.94 (s, 1H), 3.60-3.59 (m,
2H), 3.49 (m, 1H), 3.42 (m, 1H), 3.32 (m, 1H), 3.20 (m, 1H), 1.35 (s, 9H); 13C NMR (100 MHz, CDCl3) δ
169.8, 164.5, 162.1, 156.0, 143.9, 143.8, 141.3, 141.3, 138.5, 137.9, 137.6, 128.5, 128.4, 128.3, 127.9,
127.8, 127.7, 127.6, 127.5, 127.1, 125.2, 125.1, 119.9, 82.4, 77.6, 75.9, 74.6, 73.6, 73.1, 72.6, 68.0, 67.1,
50.7, 47.1, 27.8

(2S,3S,4R)-2-(N-Hexacosanoylamino)-3,4-di-tert-butyldimethylsilanyloxy-1-octadecanoic acid (36)
(2S,3S,4R)-3,4-Bis-tert-butyldimethylsilyloxy-2-hexacosanoylamino-4-octadecanol (17) (0.10 g, 0.11
mmol) was dissolved in CH2Cl2 (4.4 mL)/H2O (2.2 mL) at rt under N2. TEMPO (0.0030 g, 0.022 mmol)
followed by BAIB (0.087 g, 0.27 mmol), was added to the reaction flask. The mixture was stirred

vigorously until starting material was no longer visible via TLC (petroleum ether/EtOAc 7:3). The
reaction was diluted with CH2Cl2 (20 mL) and washed with saturated aqueous Na2S2O3 (11 mL), H2O (11
mL), and brine (11 mL). The organic layer was combined, dried (MgSO4) and concentrated under reduced
pressure. Purification by flash chromatography on silica gel (petroleum ether/EtOAc 3:2) afforded 36 as a
white solid (0.038 g, 37%): mp 75-77 °C; [α]25D -9.6 (c 0.7, CHCl3); IR (KBr) 3446, 2918, 2850, 1792,
1652 cm-1: 1H NMR (300 MHz, CDCl3) δ 6.73 (d, J = 4.9 Hz, 1H), 4.69 (d, J = 5.1 Hz, 1H), 4.01 (s, 1H),
3.80 (d, J = 7.8 Hz, 1H), 2.20 (t, J = 7.8 Hz, 2H), 1.50 (m, 8H), 1.27 (s, 65H), 0.91 (s, 6H), 0.85 (s, 18H),
0.22 (s, 3H), 0.22 (s, 3H), 0.07 (s, 3H), 0.06 (s, 3H) 13C NMR (100 MHz, CDCl3) δ 173.0, 169.5, 80.3,
79.7, 55.4, 51.7, 36.9, 34.8, 32.1, 32.0, 29.9, 29.8, 29.8, 29.7, 29.7, 29.7, 29.6, 29.5, 29.4, 26.5, 26.0, 25.9,
25.8, 25.8, 25.6, 22.7, 18.2, 18.0, 14.1, -3.9, -4.1, -4.5, -4.7; HRMS (TOF) calcd for C56H116NO5Si2 (M+ +
H) 938.84. Found 938.8387.

(2S,3R)-3-Benzyloxy-2-(N-tert-butoxycarbonyl)amino-1-octadecanoic acid (38)
(2S,3R)-2-(N-tert-Butoxycarbonyl)amino-3-benzyloxyoctadecan-1-ol (25) (0.10 g, 0.20 mmol) was
dissolved in CH2Cl2 (4.4 mL)/H2O (2.2 mL) at rt under N2. TEMPO (0.0060 g, 0.041 mmol) followed by
BAIB (0.16 g, 0.51 mmol), was added to the reaction flask. The mixture was stirred vigorously until
starting material was no longer visible via TLC (petroleum ether/EtOAc 7:3). The reaction was diluted
with CH2Cl2 (20 mL) and washed with saturated aqueous Na2S2O3 (11 mL), H2O (11 mL), and brine (11
mL). The organic layer was, dried (MgSO4), and concentrated under reduced pressure. Purification by
flash chromatography on silica gel (CH2Cl2/MeOH 99:1) afforded 38 as a light brown oil (0.083 g, 81%):
[α]25D -0.3 (c 1.8, CHCl3); IR (KBr) 3432, 2924, 2853, 1717, 1652 cm-1: 1H NMR (300 MHz, CDCl3) δ
7.22 (m, 5H), 5.15 (s, 1H), 4.62 (d, J = 11.1 Hz, 1H), 4.53 (d, J = 11.1 Hz, 1H), 3.71 (m, 1H), 1.60 (m,
2H), 1.40 (s, 9H), 1.22 (s, 26H), 0.84 (t, J = 6.9 Hz, 3H) 13C NMR (100 MHz, CDCl3) δ 175.3, 155.9,

138.1, 128.6, 128.3, 128.0, 80.4, 79.6, 72.3, 32.1, 30.9, 29.9, 29.9, 29.8, 29.8, 29.6, 28.5, 25.9, 22.9, 14.3;
HRMS (TOF) calcd for C30H52NO5 (M+ + H) 506.3845. Found 506.3887.
References
1. Morita, M.; Motoki, K.; Akimoto, K.; Natori, T.; Sakai, T.; Sawa, E.; Yamaji, K.; Koezuka, Y.;
Kobayashi, E.; Fukushima, H. J. Med. Chem. 1995, 38, 2176.
2. Dhodapkar, M. V.; Geller, M. D.; Chang, D. H.; Shimizu, K.; Fujii, S.; Dhodapkar, K. M.;
Krasovsky, J. J. Exp. Med. 2003, 197, 1667.
3. Dhodapkar, K. M.; Cirignano, B.; Finlay, J. L.; Steinman, R. M. Int. J. Canc. 2004, 109, 893.
4. Schmieg, J.; Yang, G.; Franck, R. W.; Tsuji, M. J. Exp. Med. 2003, 198, 1631.
5. Yang, G.; Schmeig, J.; Tsuji, M.; Franck, R. W. Angew. Chem. Int. Ed. 2004, 43, 3818.
6. Bharhani, M. S.; Chiu, B.; Na, K. S.; Inman, R. D. Int. Immunol. 2009, 7, 859.
7. Dombrowicz, D. Eur. J. Immunol. 2005, 10, 2786.
8. Natori, T.; Koezuka, Y.; Tatsuo, H. Tetrahedron Lett. 1993, 34, 5591.
9. Kaiser, G. E. The Adaptive Immune System. http://student.ccbcmd.edu/ (accessed December
2010).
10. Savage, P. B.; Teyton, L.; Bendelac, A. Chem. Soc. Rev. 2006, 35, 771.
11. Morita, M.; Motoki, K.; Akimoto, K.; Natori, T.; Sakai, T.; Sawa, E.; Yamaji, K.; Koezuka,
Y.; Kobayashi, E., Fukushima, H. J. Med. Chem. 1995, 38, 2176.
12. Miyamoto, K.; Miyake, S.; Yamamura, T. Nature 2001, 413, 531.

13. Chiba, A.; Oki, S.; Miyamoto, K.; Hashimoto, H.; Yamamura, T.; Miyake, S. Arthritis Rheum
2004, 50, 305.
14. Mizuno, M.; Masumura, M.; Tomi, C.; Chiba, A.; Oki, S.; Yamamura, T.; Miyake, S. J.
Autoimmunity 2004, 23, 293.
15. Brigl, M.; Bry, L.; Kent, S. C.; Gumperz, J. E.; Brenner, M. B. Nat. Immunol. 2003, 12, 1230.
16. Miyamoto, K.; Miyake, S.; Yamamura, T. Nature 2001, 413, 531.
17. Schmieg, J.; Yang, G.; Franck, R. W.; Tsuji, M. J. Exp. Med. 2003, 198, 1631.
18. Bertozzi, C. R.; Bednarski, M. D. 1996. In Modern Methods in Carbohydrate Synthesis;
Khan, S. H.; O’Neill, R. A., Eds; Harwood Academic Publishers, London, UK, 1996, pp 316.
19. Bertozzi, C. R.; Cook, D. G.; Kobertz, W. R.; Gonzalez-Scarano, F.; Bednarski, M. D. J. Am.
Chem. 1992, 114, 10639.
20. Fujii, S.; Shimizu, K.; Hemmi, H.; Fukui, M.; Bonito, A. J.; Chen, G.; Franck, R. W.; Tsuji,
M.; Steinman, R. M. Proc. Natl. Acad. Sci. U. S. A. 2006, 103, 11252.
21. Kopecky-Bromberg, S. A.; Fraser, K. A.; Pica, N.; Carnero, E.; Moran, T. M.; Franck, R. W.;
Tsuji, M.; Palese, P. Vaccine 2009, 27, 3766.
22. Blauvelt, M. L.; Khalili, M.; Jaung, W.; Paulsen, J.; Anderson, A. C.; Wilson, S. B.; Howell,
A. R. Bioorg. Med. Chem. Lett. 2008, 18, 6374.
23. Dere, R. T.; Zhu, X. Org. Lett. 2008, 10, 4641.
24. Murphy, P. V.; Bradley, H.; Tosin, M. Pitt, N.; Fitzpatrick, G. M.; Glass, W. K. J. Org.
Chem.2003, 68, 5692.
25. Retailleau, L.; Laplace, A.; Fensterbank, H.; Larpent, C. J. Org. Chem. 1998, 63, 608.

26. Du, W.; Gervay-Hague, J. Org. Lett. 2005, 7, 2063.
27. Suzuki, T.; Suzuki, S. T.; Yamada, I.; Koashi, Y.; Yamada, K.; Chida, N. J. Org. Chem. 2002,
67, 2874.
28. Li, X.; Danishefsky, S. J. J. Am. Chem. Soc. 2008, 130, 5446.
29. Passerini, M. Gazz Chim. Ital. 1921, 51, 181.
30. Sanghee, K.; Song, S.; Lee, T.; Jung, S.; Kim, D. Synthesis 2004, 6, 847.
31. Swamy, N.; Ray, R. Bioorg. Chem. 2008, 36, 165.
32. Sen, S. E.; Roach, S. L. Synthesis 1995, 7, 756.
33. Ndonye, R. M.; Izmirian, D. P.; Dunn, M. F.; Yu, K. O. A.; Porcelli, S. A.; Khurana, A.;
Kronenberg, M.; Richardson, S. K.; Howell, A. R. J. Org. Chem. 2005, 70, 10260.
34. Osby, J. O.; Martin, M. G.; Ganem, B. Tetrahedron Lett 1984, 25, 2093.
35. Kulkarni, S. S.; Gervay-Hague, J. Org. Lett.2006, 8, 5765.
36. Wu, X.; Li, X.; Danishefsky, S. J. Tetrahedron Lett. 2009, 50, 1523.
37. Kronzer, F. J.; Schuerch, C. Carbohydr. Res. 1974, 33, 273.

